Open Payments

RAMEZ NASSEF ESKANDER

Type
Physician · Allopathic & Osteopathic Physicians / Obstetrics & Gynecology
Where
ENCINITAS, CA
NPI
1144486929
Received
$706,485 in 526 records, 2019 to 2025
As principal investigator
$7,460,305 of research payments to others in 74 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment92$169,928
2024General payment91$111,691
2023General payment91$115,388
2022General payment61$78,409
2021General payment43$63,297
2020General payment50$65,841
2019General payment98$101,928

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC116$202,3522019–2025
AstraZeneca Pharmaceuticals LP114$153,6232019–2025
Eisai Inc.61$73,2702019–2025
GlaxoSmithKline, LLC.40$56,4692020–2025
AstraZeneca UK Limited12$28,5502019–2025
Clovis Oncology, Inc.19$23,5642019–2022
ABBVIE INC.15$22,3832024–2025
Regeneron Pharmaceuticals, Inc.20$22,0452023–2025
Genmab U.S., Inc.14$19,1132022–2025
SEAGEN INC.19$18,9022021–2023
Daiichi Sankyo Inc.12$15,8692021–2025
Myriad Genetic Laboratories, Inc.17$15,3312020–2022
ImmunoGen, Inc.8$6,8522023–2024
Corcept Therapeutics6$5,4832024–2025
BioNTech SE6$5,4362023–2024
BeOne Medicines USA, Inc.4$5,2002025
Gilead Sciences, Inc.6$5,1702023–2025
BeiGene USA, Inc.2$3,9002024
Eli Lilly and Company3$3,4822025
Eisai Co., Ltd.1$3,1602023
Incyte Corporation2$3,1482024–2025
Aadi Bioscience, Inc.2$3,1062023
Novocure GmbH1$2,4002023
TESARO, Inc.7$2,1542019
PFIZER INC.5$2,0052019–2024
Novartis Pharmaceuticals Corporation1$1,7222021
F. Hoffmann-La Roche AG1$7602024
Intuitive Surgical, Inc.2$3362019–2020
Foundation Medicine, Inc.1$2292022
Novocure Inc.4$1662021–2022
Karyopharm Therapeutics Inc.2$1362023–2025
Genentech USA, Inc.1$1262019
Amgen Inc.1$172020
Medical Device Business Services, Inc.1$132023

By nature of payment

NatureRecordsAmount
Consulting Fee161$379,756
Compensation for services other than consulting, including serving as faculty or as a speaker at a v69$225,113
Travel and Lodging91$79,122
Food and Beverage195$12,945
Honoraria6$7,325
Education4$2,221

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-23Daiichi Sankyo Inc.$1,453Consulting FeeCash or cash equivalent2025
2025-12-10Merck Sharp & Dohme LLC$2,880Consulting FeeCash or cash equivalent2025
2025-12-02BeOne Medicines USA, Inc.$1,625Consulting FeeCash or cash equivalent2025
2025-11-21Gilead Sciences, Inc.$2,710Consulting FeeCash or cash equivalent2025
2025-11-17Merck Sharp & Dohme LLC$7,680Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-11-17Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2025
2025-11-07Merck Sharp & Dohme LLC$123Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-11-07Merck Sharp & Dohme LLC$26Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-11-06ABBVIE INC.$47Food and BeverageIn-kind items and servicesELAHERE Drug, ONCOLOGY2025
2025-11-05Corcept Therapeutics$94Food and BeverageIn-kind items and servicesKorlym Drug, Endocrinology2025
2025-11-04Merck Sharp & Dohme LLC$123Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-10-31AstraZeneca UK Limited$410Consulting FeeCash or cash equivalentENHERTU Biological, Oncology2025
2025-10-24Genmab U.S., Inc.$2,000Consulting FeeIn-kind items and servicesEpkinly Drug, Oncology2025
2025-10-24AstraZeneca Pharmaceuticals LP$1,370Consulting FeeCash or cash equivalentLYNPARZA Drug, Oncology2025
2025-10-17Gilead Sciences, Inc.$17Food and BeverageIn-kind items and services2025
2025-10-17Gilead Sciences, Inc.$17Food and BeverageIn-kind items and services2025
2025-10-16Genmab U.S., Inc.$150Food and BeverageIn-kind items and services2025
2025-10-16Genmab U.S., Inc.$28Food and BeverageIn-kind items and services2025
2025-10-06Merck Sharp & Dohme LLC$896Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-09-29Merck Sharp & Dohme LLC$7,680Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-09-29Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2025
2025-09-20Merck Sharp & Dohme LLC$60Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-09-19Merck Sharp & Dohme LLC$161Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-09-19Merck Sharp & Dohme LLC$34Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-09-19Merck Sharp & Dohme LLC$34Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-09-18Merck Sharp & Dohme LLC$9,972Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-09-18Merck Sharp & Dohme LLC$161Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-09-18Merck Sharp & Dohme LLC$56Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-09-18Merck Sharp & Dohme LLC$53Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-09-17Merck Sharp & Dohme LLC$7,680Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-09-12BeOne Medicines USA, Inc.$650Consulting FeeCash or cash equivalent2025
2025-09-11Merck Sharp & Dohme LLC$578Travel and LodgingIn-kind items and services2025
2025-09-11Merck Sharp & Dohme LLC$115Travel and LodgingIn-kind items and services2025
2025-09-10Merck Sharp & Dohme LLC$7,799Travel and LodgingIn-kind items and services2025
2025-08-01Genmab U.S., Inc.$800Consulting FeeIn-kind items and servicesEpkinly Drug, Oncology2025
2025-07-30Merck Sharp & Dohme LLC$10,880Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-07-30Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2025
2025-07-25Genmab U.S., Inc.$3,200Consulting FeeIn-kind items and servicesEpkinly Drug, Oncology2025
2025-07-19Merck Sharp & Dohme LLC$20Food and BeverageIn-kind items and services2025
2025-07-18Merck Sharp & Dohme LLC$7,418Travel and LodgingIn-kind items and services2025
2025-07-18Merck Sharp & Dohme LLC$207Travel and LodgingIn-kind items and services2025
2025-07-10GlaxoSmithKline, LLC.$6,400Consulting FeeCash or cash equivalent2025
2025-07-09BeOne Medicines USA, Inc.$1,950Consulting FeeCash or cash equivalent2025
2025-06-02AstraZeneca Pharmaceuticals LP$1,370Consulting FeeCash or cash equivalent2025
2025-06-01Eli Lilly and Company$2,139EducationIn-kind items and services2025
2025-06-01Eli Lilly and Company$93Food and BeverageIn-kind items and services2025
2025-05-30Corcept Therapeutics$3,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-05-30Corcept Therapeutics$132Food and BeverageIn-kind items and services2025
2025-05-30GlaxoSmithKline, LLC.$95Food and BeverageIn-kind items and services2025
2025-05-30Corcept Therapeutics$38Food and BeverageIn-kind items and services2025
2025-05-16BeOne Medicines USA, Inc.$975Consulting FeeCash or cash equivalent2025
2025-05-02Regeneron Pharmaceuticals, Inc.$3,600Consulting FeeCash or cash equivalent2025
2025-05-02Regeneron Pharmaceuticals, Inc.$1,800Consulting FeeCash or cash equivalent2025
2025-05-02GlaxoSmithKline, LLC.$1,200Consulting FeeCash or cash equivalent2025
2025-04-26AstraZeneca Pharmaceuticals LP$12Food and BeverageIn-kind items and services2025
2025-04-23GlaxoSmithKline, LLC.$7,200Consulting FeeCash or cash equivalent2025
2025-04-23Eisai Inc.$2,445Consulting FeeCash or cash equivalent2025
2025-04-07Merck Sharp & Dohme LLC$10,370Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-04-07Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2025
2025-04-02Eisai Inc.$3,667Consulting FeeCash or cash equivalentLenvima Drug, Oncology2025
2025-03-31Merck Sharp & Dohme LLC$19Food and BeverageIn-kind items and services2025
2025-03-30Merck Sharp & Dohme LLC$19Food and BeverageIn-kind items and services2025
2025-03-29Merck Sharp & Dohme LLC$8,870Travel and LodgingIn-kind items and services2025
2025-03-29Merck Sharp & Dohme LLC$635Travel and LodgingIn-kind items and services2025
2025-03-29Merck Sharp & Dohme LLC$158Travel and LodgingIn-kind items and services2025
2025-03-19Daiichi Sankyo Inc.$1,860Consulting FeeCash or cash equivalent2025
2025-03-17Regeneron Pharmaceuticals, Inc.$130Food and BeverageIn-kind items and services2025
2025-03-17Regeneron Pharmaceuticals, Inc.$37Food and BeverageIn-kind items and services2025
2025-03-17Regeneron Pharmaceuticals, Inc.$23Food and BeverageIn-kind items and services2025
2025-03-14Daiichi Sankyo Inc.$50Food and BeverageIn-kind items and services2025
2025-03-14Daiichi Sankyo Inc.$26Food and BeverageIn-kind items and services2025
2025-03-12Daiichi Sankyo Inc.$1,860Consulting FeeCash or cash equivalent2025
2025-03-11Incyte Corporation$3,105Consulting FeeCash or cash equivalent2025
2025-03-07AstraZeneca UK Limited$4,100Consulting FeeCash or cash equivalent2025
2025-03-03Merck Sharp & Dohme LLC$3,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-03-03Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2025
2025-02-24AstraZeneca Pharmaceuticals LP$685Consulting FeeCash or cash equivalent2025
2025-02-21Regeneron Pharmaceuticals, Inc.$3,150Consulting FeeCash or cash equivalent2025
2025-02-21Regeneron Pharmaceuticals, Inc.$900Consulting FeeCash or cash equivalent2025
2025-02-21Karyopharm Therapeutics Inc.$51Food and BeverageIn-kind items and servicesXPOVIO Drug, Oncology2025
2025-02-21Merck Sharp & Dohme LLC$31Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-02-20Merck Sharp & Dohme LLC$43Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-02-19ABBVIE INC.$5,800Consulting FeeCash or cash equivalent2025
2025-02-05Eisai Inc.$4,890Consulting FeeCash or cash equivalentLenvima Drug, Oncology2025
2025-02-05GlaxoSmithKline, LLC.$1,809Travel and LodgingIn-kind items and services2025
2025-02-05GlaxoSmithKline, LLC.$192Travel and LodgingIn-kind items and services2025
2025-02-05GlaxoSmithKline, LLC.$169Travel and LodgingIn-kind items and services2025
2025-02-05GlaxoSmithKline, LLC.$62Food and BeverageIn-kind items and services2025
2025-02-05GlaxoSmithKline, LLC.$48Food and BeverageIn-kind items and services2025
2025-02-05GlaxoSmithKline, LLC.$48Food and BeverageIn-kind items and services2025
2025-02-05GlaxoSmithKline, LLC.$39Food and BeverageIn-kind items and services2025
2025-01-24Eli Lilly and Company$1,250Consulting FeeCash or cash equivalent2025
2024-12-16Merck Sharp & Dohme LLC$4,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-09GlaxoSmithKline, LLC.$1,600Consulting FeeCash or cash equivalentJEMPERLI Biological, ONCOLOGY2024
2024-11-20AstraZeneca UK Limited$4,110Consulting FeeCash or cash equivalent2024
2024-11-20GlaxoSmithKline, LLC.$600Consulting FeeCash or cash equivalent2024
2024-11-18Merck Sharp & Dohme LLC$6,710Consulting FeeCash or cash equivalent2024
2024-11-18Merck Sharp & Dohme LLC$5,490Consulting FeeCash or cash equivalent2024
2024-11-18Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2024
2024-11-18Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2024
2024-11-13BeiGene USA, Inc.$1,950Consulting FeeCash or cash equivalent2024
2024-11-13BeiGene USA, Inc.$1,950Consulting FeeCash or cash equivalent2024
2024-11-12GlaxoSmithKline, LLC.$1,600Consulting FeeCash or cash equivalent2024
2024-11-09Merck Sharp & Dohme LLC$55Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-09Merck Sharp & Dohme LLC$48Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-09Merck Sharp & Dohme LLC$45Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-08Merck Sharp & Dohme LLC$288Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-08Merck Sharp & Dohme LLC$247Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-08Merck Sharp & Dohme LLC$208Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-08Merck Sharp & Dohme LLC$95Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-08Merck Sharp & Dohme LLC$55Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-08Merck Sharp & Dohme LLC$48Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-08Merck Sharp & Dohme LLC$45Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-07Merck Sharp & Dohme LLC$729Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-07Merck Sharp & Dohme LLC$388Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-07Merck Sharp & Dohme LLC$247Travel and LodgingIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-11-06AstraZeneca UK Limited$2,460Consulting FeeCash or cash equivalent2024
2024-10-25AstraZeneca Pharmaceuticals LP$1,370Consulting FeeCash or cash equivalent2024
2024-10-25ABBVIE INC.$596Travel and LodgingIn-kind items and services2024
2024-10-25ABBVIE INC.$48Food and BeverageIn-kind items and services2024
2024-10-25ABBVIE INC.$34Food and BeverageIn-kind items and services2024
2024-10-25ABBVIE INC.$14Food and BeverageIn-kind items and services2024
2024-10-25ABBVIE INC.$14Food and BeverageIn-kind items and services2024
2024-10-24ABBVIE INC.$233Travel and LodgingIn-kind items and services2024
2024-10-17AstraZeneca UK Limited$60Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2024
2024-10-16Incyte Corporation$43Food and BeverageCash or cash equivalent2024
2024-10-11GlaxoSmithKline, LLC.$1,600Consulting FeeCash or cash equivalent2024
2024-10-07Merck Sharp & Dohme LLC$2,440Consulting FeeCash or cash equivalent2024
2024-09-23Merck Sharp & Dohme LLC$4,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-09-23Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2024
2024-09-20Regeneron Pharmaceuticals, Inc.$3,150Consulting FeeCash or cash equivalent2024
2024-09-20Regeneron Pharmaceuticals, Inc.$900Consulting FeeCash or cash equivalent2024
2024-09-16Merck Sharp & Dohme LLC$66Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-09-16GlaxoSmithKline, LLC.$47Food and BeverageIn-kind items and services2024
2024-09-16GlaxoSmithKline, LLC.$24Food and BeverageIn-kind items and services2024
2024-09-15Merck Sharp & Dohme LLC$281Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-09-15Merck Sharp & Dohme LLC$26Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-09-14Genmab U.S., Inc.$131Food and BeverageIn-kind items and servicesEpkinly Drug, Oncology2024
2024-09-14Merck Sharp & Dohme LLC$40Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2024
2024-09-13BioNTech SE$74Food and BeverageIn-kind items and services2024
2024-09-13BioNTech SE$17Food and BeverageIn-kind items and services2024
2024-09-12Corcept Therapeutics$1,950Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentKorlym Drug, Endocrinology2024
2024-09-12PFIZER INC.$134Food and BeverageIn-kind items and servicesTIVDAK Biological, Oncology2024
2024-09-12Corcept Therapeutics$67Food and BeverageCash or cash equivalentKorlym Drug, Endocrinology2024
2024-08-28Merck Sharp & Dohme LLC$6,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-08-20Eisai Inc.$20Food and BeverageIn-kind items and servicesLenvima Drug, Oncology2024
2024-08-05GlaxoSmithKline, LLC.$2,400Consulting FeeCash or cash equivalent2024
2024-07-19ABBVIE INC.$2,450Consulting FeeCash or cash equivalentELAHERE Drug, ONCOLOGY2024
2024-07-17Eisai Inc.$3,260Consulting FeeCash or cash equivalent2024
2024-07-14ABBVIE INC.$2,800Consulting FeeCash or cash equivalentELAHERE Drug, ONCOLOGY2024
2024-07-14ABBVIE INC.$46Travel and LodgingCash or cash equivalentELAHERE Drug, ONCOLOGY2024
2024-07-08AstraZeneca Pharmaceuticals LP$1,370Consulting FeeCash or cash equivalent2024
2024-07-04PFIZER INC.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTIVDAK Biological, Oncology2024
2024-06-20ABBVIE INC.$86Food and BeverageIn-kind items and servicesELAHERE Drug, ONCOLOGY2024
2024-06-20GlaxoSmithKline, LLC.$75Food and BeverageIn-kind items and services2024
2024-06-18ABBVIE INC.$44Food and BeverageIn-kind items and servicesELAHERE Drug, ONCOLOGY2024
2024-06-14AstraZeneca Pharmaceuticals LP$1,370Consulting FeeCash or cash equivalent2024
2024-06-02Regeneron Pharmaceuticals, Inc.$99Food and BeverageIn-kind items and services2024
2024-06-01PFIZER INC.$195Food and BeverageIn-kind items and servicesTIVDAK Biological, Oncology2024
2024-05-29Eisai Inc.$3,667Consulting FeeCash or cash equivalentLenvima Drug, Oncology2024
2024-05-29ABBVIE INC.$669Travel and LodgingCash or cash equivalentELAHERE Drug, ONCOLOGY2024
2024-05-21ABBVIE INC.$9,495Travel and LodgingCash or cash equivalentELAHERE Drug, ONCOLOGY2024
2024-05-17GlaxoSmithKline, LLC.$2,400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-04-24Eisai Inc.$2,445Consulting FeeCash or cash equivalentLenvima Drug, Oncology2024
2024-04-03AstraZeneca Pharmaceuticals LP$1,370Consulting FeeCash or cash equivalent2024
2024-03-21Daiichi Sankyo Inc.$1,240Consulting FeeCash or cash equivalent2024
2024-03-18Eisai Inc.$64Food and BeverageCash or cash equivalentLenvima Drug, Oncology2024
2024-02-22GlaxoSmithKline, LLC.$2,800Consulting FeeCash or cash equivalentZEJULA Drug, ONCOLOGY2024
2024-02-13AstraZeneca Pharmaceuticals LP$2,740Consulting FeeCash or cash equivalentLYNPARZA Drug, Oncology2024
2024-02-10AstraZeneca Pharmaceuticals LP$36Food and Beverage (4 payments)In-kind items and services2024
2024-02-01F. Hoffmann-La Roche AG$760Consulting FeeCash or cash equivalentTecentriq Biological, BioOncology2024
2024-01-29Merck Sharp & Dohme LLC$2,135Consulting FeeCash or cash equivalent2024
2024-01-26ImmunoGen, Inc.$1,400Consulting FeeCash or cash equivalentELAHERE Drug, ONCOLOGY2024
2024-01-26ImmunoGen, Inc.$79Food and BeverageIn-kind items and servicesELAHERE Drug, ONCOLOGY2024
2024-01-26AstraZeneca Pharmaceuticals LP$68Food and BeverageIn-kind items and servicesLYNPARZA Drug, Oncology2024
2024-01-26AstraZeneca Pharmaceuticals LP$53Food and BeverageIn-kind items and servicesLYNPARZA Drug, Oncology2024
2024-01-26AstraZeneca Pharmaceuticals LP$29Food and BeverageIn-kind items and servicesLYNPARZA Drug, Oncology2024
2024-01-24Eisai Inc.$110Food and BeverageIn-kind items and services2024
2024-01-24GlaxoSmithKline, LLC.$28Food and BeverageIn-kind items and services2024
2024-01-18GlaxoSmithKline, LLC.$3,600Consulting FeeCash or cash equivalentJEMPERLI Biological, ONCOLOGY2024
2024-01-16ImmunoGen, Inc.$118Food and BeverageIn-kind items and servicesELAHERE Drug, ONCOLOGY2024
2024-01-08Regeneron Pharmaceuticals, Inc.$2,641Consulting FeeCash or cash equivalent2024
2024-01-08Regeneron Pharmaceuticals, Inc.$587Consulting FeeCash or cash equivalent2024
2023-12-22AstraZeneca UK Limited$2,055Consulting FeeCash or cash equivalent2023
2023-12-13Eisai Inc.$2,445Consulting FeeCash or cash equivalent2023
2023-12-08BioNTech SE$2,750Consulting FeeCash or cash equivalent2023
2023-12-08GlaxoSmithKline, LLC.$1,200Consulting FeeCash or cash equivalentZEJULA Drug, ONCOLOGY2023
2023-12-08ImmunoGen, Inc.$80Food and BeverageIn-kind items and servicesElahere Biological, Oncology2023
2023-12-04BioNTech SE$53Food and BeverageIn-kind items and services2023
2023-12-03BioNTech SE$2,181Travel and LodgingIn-kind items and services2023
2023-12-03BioNTech SE$360Travel and LodgingIn-kind items and services2023
2023-11-30SEAGEN INC.$2,380Consulting FeeCash or cash equivalent2023
2023-11-30Daiichi Sankyo Inc.$1,612Consulting FeeCash or cash equivalent2023
2023-11-22Eisai Co., Ltd.$3,160Consulting FeeCash or cash equivalentLenvima Drug, Oncology2023
2023-11-13Merck Sharp & Dohme LLC$4,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-11-13Merck Sharp & Dohme LLC$150Travel and LodgingCash or cash equivalent2023
2023-11-12AstraZeneca Pharmaceuticals LP$685Consulting FeeCash or cash equivalentLYNPARZA Drug, Oncology2023
2023-11-10Regeneron Pharmaceuticals, Inc.$80Food and BeverageIn-kind items and services2023
2023-11-10Regeneron Pharmaceuticals, Inc.$67Food and BeverageIn-kind items and services2023
2023-11-06Merck Sharp & Dohme LLC$6,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023

The latest 200 records of 526.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-31ABBVIE INC.University Of California San Diego Jacobs Medical Center$840A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FR Antibody-drug Conjugate) 2025
2025-12-31Merck Sharp & Dohme LLCNRG Oncology$127,915A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR2025
2025-12-31Merck Sharp & Dohme LLCMoores Cancer Center$15,766A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2025
2025-12-04ABBVIE INC.UC SAN DIEGO MOORES CANCER CENTER$4,280Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tu2025
2025-11-06Genmab U.S., Inc.Langley Porter Psychiatric Hospital$17,839A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) i2025
2025-07-17ABBVIE INC.UC SAN DIEGO MOORES CANCER CENTER$14,797Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tu2025
2025-05-15Eli Lilly and CompanyREGENTS OF THE UNIVERSITY OF CALIFORNIA$231,628A FIRST IN HUMAN PHASE 1A AND 1B TRIAL TO ASSESS THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF LY4170156 AN ANTIBO2025
2025-04-03Genmab U.S., Inc.UC SAN DIEGO MOORES CANCER CENTER$35,000A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) i2025
2024-12-31Merck Sharp & Dohme LLCNRG Oncology$1,047,904A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR2024
2024-12-31Merck Sharp & Dohme LLCNRG Oncology$1,462,215A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR2024
2024-12-31Merck Sharp & Dohme LLCMoores UC San Diego Cancer Ctr$129,632A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2024
2024-10-28ABBVIE INC.UC SAN DIEGO MOORES CANCER CENTER$9,286Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F2024
2024-10-28ABBVIE INC.UC SAN DIEGO MOORES CANCER CENTER$10,700Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F2024
2024-05-28ABBVIE INC.UC SAN DIEGO MOORES CANCER CENTER$4,253Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F2024
2024-02-23ABBVIE INC.UC SAN DIEGO MOORES CANCER CENTER$33,729Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F2024
2023-12-31AstraZeneca Pharmaceuticals LPUCLA - NEURO ONCOLOGY$187A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato-2023
2023-12-31Merck Sharp & Dohme LLCMoores Cancer Center$28,472A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2023
2023-12-31Merck Sharp & Dohme LLCMoores Cancer Center$18,160A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2023
2023-12-31Merck Sharp & Dohme LLCMoores Cancer Center$1,410A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2023
2023-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$20,173A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With2023
2023-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$3,552A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR2023
2023-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$13,831A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR2023
2023-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$9,531A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With2023
2023-10-02Novocure Inc.UC SAN DIEGO MOORES CANCER CENTER$4,500EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2023
2023-07-26AstraZeneca Pharmaceuticals LPUCLA - NEURO ONCOLOGY$17,290A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato-2023
2023-03-20Novocure Inc.UC SAN DIEGO MOORES CANCER CENTER$750EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2023
2023-03-08Epizyme, Inc.UCSD MOORES CANCER CENTER$50,000A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary2023
2022-12-31Merck Sharp & Dohme LLCMoores Cancer Center$2,370A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2022
2022-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$12,598A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With2022
2022-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$18,169A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With2022
2022-12-31Merck Sharp & Dohme LLCMoores Cancer Center$4,997A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2022
2022-12-31Merck Sharp & Dohme LLCMoores Cancer Center$14,156A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem2022
2022-12-31Merck Sharp & Dohme LLCNRG Oncology$3,159,889A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC 776864 IN ADDITION TO PACLITAXEL AND CARB2022
2022-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$26,064A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With2022
2022-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$2,982A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With2022
2022-10-19MACROGENICS, INC.RAMEZ N ESKANDER MD$3,0002022
2022-10-13Clovis Oncology, Inc.The Regents of the Univ of Californ$6,965A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2022
2022-09-08Clovis Oncology, Inc.The Regents of the Univ of Californ$16,021A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2022
2022-08-09Clovis Oncology, Inc.The Regents of the Univ of Californ$3,509A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2022
2022-07-21AstraZeneca UK LimitedUC REGENTS$66,047A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for2022
2022-05-03Clovis Oncology, Inc.The Regents of the Univ of Californ$20,150A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2022
2022-05-03Clovis Oncology, Inc.The Regents of the Univ of Californ$1,448A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2022
2022-03-29F. Hoffmann-La Roche AGThe Regents of the University of California, San Diego$3,562PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2022
2022-02-22Novocure Inc.UC SAN DIEGO MOORES CANCER CENTER$4,012EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2022
2022-02-15F. Hoffmann-La Roche AGThe Regents of the University of California, San Diego$1,251PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2022
2022-02-01F. Hoffmann-La Roche AGThe Regents of the University of California, San Diego$4,550PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2022
2022-02-01F. Hoffmann-La Roche AGThe Regents of the University of California, San Diego$4,599PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2022
2022-01-25F. Hoffmann-La Roche AGThe Regents of the University of California, San Diego$7,067PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2022
2021-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$26,064A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With2021
2021-12-31Merck Sharp & Dohme LLCUCSD MOORES CANCER CENTER$20,334A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With2021
2021-12-30F. Hoffmann-La Roche AGUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$7,218PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-10-14Clovis Oncology, Inc.The Regents of the Univ of Californ$13,299A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2021
2021-09-29F. Hoffmann-La Roche AGUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$1,462PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-09-28Novocure Inc.UC SAN DIEGO MOORES CANCER CENTER$32,650EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2021
2021-09-27Novocure Inc.UC SAN DIEGO MOORES CANCER CENTER$82,650EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2021
2021-09-21Clovis Oncology, Inc.The Regents of the Univ of Californ$46,878A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2021
2021-08-10Clovis Oncology, Inc.The Regents of the Univ of Californ$20,150A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2021
2021-08-10Clovis Oncology, Inc.The Regents of the Univ of Californ$22,655A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2021
2021-08-03F. Hoffmann-La Roche AGUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$26PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-07-27F. Hoffmann-La Roche AGUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$8,284PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-07-07F. Hoffmann-La Roche AGUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$24,999PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-06-24AstraZeneca UK LimitedTHE REGENTS OF THE UNIVERSITY OF$56,680A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for2021
2021-06-24Clovis Oncology, Inc.The Regents of the Univ of Californ$53,195A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2021
2021-04-27F. Hoffmann-La Roche AGUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$16,158PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2021-04-13Clovis Oncology, Inc.The Regents of the Univ of Californ$75,676A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2021
2021-04-12AstraZeneca UK LimitedREGENTS OF THE UNIVERSITY OF CALIFORNIA - UCSF$69,800A Phase 2 Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment 2021
2021-03-08Clovis Oncology, Inc.The Regents of the Univ of Californ$3,510A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2021
2021-02-23Clovis Oncology, Inc.The Regents of the Univ of Californ$27,780A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2021
2021-01-25F. Hoffmann-La Roche AGUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$15,307PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2021
2020-12-21Clovis Oncology, Inc.The Regents of The University of California$57,852A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor2020
2020-04-13F. Hoffmann-La Roche AGUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$15,671PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2020
2020-02-12PFIZER INC.The Regents of The University of California$8,710A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHE2020
2019-07-10Genentech, Inc.REGENTS OF THE UNIVERSITY OF CALIFORNIA TECHNOLOGY TRANSFER OFFICE$27,820BETI SOLID TUMOR PHASE 1B2019
2019-04-29Roche Products LimitedUNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE$28,405PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Diego CountyEncinitas city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Encinitas, CA, county San Diego County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Encinitas, CA
County
San Diego County, CA
State
California
Population B0100361,4803,288,77439,287,377
Population, 2020 census P162,0073,298,63439,538,223
Median age B0100243.137.337.9
Under 18 B0100120.7%20.9%22.0%
65 and over B0100119.9%15.4%15.7%
Households B1100123,9271,171,27813,548,091
Foreign born B0500212.8%22.8%27.0%
Median household income B19013$162,229$106,268$99,122
Median family income B19113$184,771$122,377$113,346
Per capita income B19301$84,594$51,976$49,513
Poverty rate B170017.4%10.3%12.0%
Unemployment rate B230254.5%6.1%6.6%
Civilian labor force B2302533,3741,689,38420,068,466
Mean commute (minutes) B0801324.725.528.7
Bachelor's degree or higher B1500367.7%43.2%37.1%
Housing units B2500126,2301,250,64114,644,735
Owner-occupied B2500366.5%54.6%55.9%
Renters B2500333.5%45.4%44.1%
Median home value B25077$1,646,800$854,700$734,700
Median gross rent B25064$2,886$2,246$2,036
White, not Hispanic B0300273.3%42.4%33.8%
Black B030020.4%4.4%5.2%
Hispanic or Latino B0300216.4%34.6%40.2%
Asian B030024.2%12.1%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Encinitas, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.